knowledge -WSS

knowledge

author：leisure time 2025-09-05 07:00:02 - browse：586

Under the Affordable Care Act, health insurers are required to cover all costs associated with preventive care — including PrEP, or pre-exposure prophylactic treatment for HIV. But now all preventive care coverage is under threat, thanks to a lawsuit filed by employers who believe they shouldn’t be required to pay for care that violates their religious beliefs.

While coverage for PrEP access is largely unchanged as the court case makes its way through the legal system, Richard Hughes IV, a partner with the law firm Epstein Becker Green, says that protecting the status quo isn’t enough. For instance, currently you have to jump through extra hoops to get long-acting injectable PrEP covered by insurance.

But Hughes has a better idea for how to not only protect but also expand access to PrEP.

On this episode of the “First Opinion Podcast,” I spoke to Hughes about his proposal, why access to PrEP has never been what it should be, the Supreme Court’s current approach to health care, and more.

“If a provider has a bad experience with a previous patient experiencing non-coverage, they might say to the next patient, ‘Well, I’m not sure this is going to be covered.’ And that can be really discouraging,” Hughes said. “What we really need to create that clarity for patients is for this law to be upheld, for the recommendations to be clear, and for providers to have the assurance that they will be covered by payers.”

Our conversation was based on his recent First Opinion op-ed, “How to protect PrEP coverage, no matter what happens in Braidwood v. Becerra.”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.

And if you have any feedback for us — First Opinion authors to feature on the podcast, kudos, or darts — email us at [email protected] and please put “podcast” in the subject line.

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Albert Bourla of Pfizer: worst biopharma CEO of 2023

hotspot

WSS

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Three trends to watch in biotech in 2024

In boost for rare disease push, AstraZeneca to buy Amolyt Pharma

Medicare Advantage beneficiaries sue Humana over algorithm use

Amid AI frenzy, a top HHS official's quest to create safeguards

Why depression after traumatic brain injury is distinct

hotspot

knowledge

entertainment

After affirmative action ruling, medical educators look to 'holistic review'

As AI in medicine takes off, can 'human in the loop' prevent harm?

BioMarin wins approval for gene therapy to treat hemophilia A

Editas, Vertex strike deal on CRISPR

Bright Health sells Medicare Advantage business to Molina

Boston's new lab space is opening empty

At least 13 dead in Texas as scorching temps continue

Carvykti CAR

Heart attack and stroke risk calculators need revising

How to save health care price transparency rules

Wikipedia

Why health care costs have stayed mostly flat since 2010

Pushing for an NIH office for post

First U.S. drug developed to treat liver disease MASH is approved

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Why health care costs have stayed mostly flat since 2010

Hospitals owned by private equity see complications spike 25%

focus

hotspot

hotspot

explore